Circe Biomedical, Inc.

Claudy Jean-Paul Mullon

Hugo O Jauregui

Timothy Jon Perlman

Shawn P Cain

Donna M Trenkler

Sharda Naik

Henry A Santangini

An artificial liver support system is described herein which comprises cryopreserved hepatocytes having an initial viability of 80-99%. Further disclosed are hepatocytes cryopreserved by dispensing hepatocytes into freezing containers, freezing the containers from between minus 50 to minus 90 degrees Celsius, storing the containers in liquid or vapor nitrogen, thawing the cryopreserved hepatocytes when ready for use and removing residual cryoprotectant media.

Method of cryopreserving hepatocytes

An artificial liver support system is described herein which comprises cryopreserved hepatocytes having an initial viability of 80-99% and a metabolic activity 50-80% of fresh hepatocytes. Further disclosed are hepatocytes cryopreserved by dispensing hepatocytes into freezing containers, freezing the containers from between minus 50 to minus 90 degrees Celsius, storing the containers in liquid or vapor nitrogen, thawing the cryopreserved hepatocytes when ready for use and removing residual cryoprotectant media.

Cryopreserved hepatocytes and high viability and metabolic activity

Growing community of inventors

Framingham, MA, United States of America

Claudy Jean-Paul Mullon